Beijing Lianxin Pharmaceutical Co., Ltd. was established in 1999 and initiated by the artificial musk research unit. It was approved by the former Ministry of Health, the State Administration of Traditional Chinese Medicine and other relevant departments, and was established in accordance with the modern enterprise system. The company is the production of artificial musk. enterprise. The company has a registered capital of 60 million yuan. It is located in the Daxing Biomedical Industry Base in Zhongguancun Science and Technology Park, Daxing District, Beijing. The factory covers an area of ​​50 mu and has a total construction area of ​​more than 30,000 square meters.

The company is invested and established by four shareholders, namely the Institute of Pharmaceuticals of the Chinese Academy of Medical Sciences, Shandong Hongjitang Pharmaceutical Group Co., Ltd., Shanghai Medicinal Materials Co., Ltd., and China Traditional Chinese Medicine Co., Ltd., and has a shareholders' meeting, a board of directors, a board of supervisors and an executive level. The company has passed GMP certification and ISO9001:2015 certification and is a tax-paying unit in Beijing and a national high-tech enterprise.

The company owns the first-class new drug, the National Drug Approval Z20040042 artificial musk, is a major scientific research achievement and confidential variety in the country.

The company adheres to the quality policy of "integrity, harmony and innovation", strives to overcome industrial production technology and in-depth research on products, improve quality control and management systems, continuously promote technological innovation, improve output, and produce stable artificial musk products on a large scale. , meet people's needs for medication. The company will also increase research on alternatives to endangered animal medicinal materials and make greater contributions to the traditional Chinese medicine industry.